Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

By sjmartinez • April 23, 2024

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01147-7. Epub ahead of print. PMID: 38647975.

Tags: Clinical outcomes, Dermatology, ixekizumab, long-term, patient-reported outcomes, psoriasis, Publications, Quality of Life, Scalp clearance

TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma

Gross L, Mutisheva I, Hillen H, Robatel S, Wartenberg M, Ma F, Bäriswyl L, Lee DJ, Modlin RL, Z'graggen K, Schenk M. TREM-1 as a[...]

New-Onset Perianal Eroded Lesion in a Pediatric Patient

Yan MJ, Galamgam J, Shen A, Mo J, Hogeling M. New-Onset Perianal Eroded Lesion in a Pediatric Patient. Pediatr Dermatol. 2025 Sep 8. doi: 10.1111/pde.70037.[...]

Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy

Burshtein J, Bunick CG, Vleugels RA, Armstrong AW, Golant AK, Schlesinger T, Strober BE, Song EJ, Gold LS, Lebwohl M. Systemic Corticosteroid Use in Atopic[...]